Applied Genetic Technologies Corp (NASDAQ: AGTC) today conveyed 12-month statistics from its ongoing achromatopsia (ACHM) Phase 1/2 scientific trials, including statistics from all adult patients and low-dose pediatric patients. Consequences reveal biological movement based on enhancements in visual sensitivity For its ACHM B3 applicant, results validate biologic activity based on […]